Steady state is reached within two to three days of once-daily administration of degludec, a basal insulin with an ultra-long duration of action

Article Authors: Tim Heise, Stefan Korsatko, Leszek Nosek, Hans Veit Coester, Sigrid Deller, Carsten Roepstorff, Stine Segel, Rahul Kapur, Hanne Haahr, Marcus Hompesch


Various factors influence the pharmacokinetic and pharmacodynamic properties of insulin analogs. The aim of the present study was to determine time to steady state of insulin degludec (IDeg), a basal insulin analog with an ultralong duration of action, after once-daily subcutaneous administration in subjects of varying age, diabetes type, and ethnicity.